Higher immunoadjuvant activities of N-acetyl-beta-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine in comparison with N-acetylmuramyl-L-alanyl-D-isoglutamine.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000276:Adjuvants, Immunologic; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D003315:Cornea / Q000187:drug effects; D005260:Female; D006020:Glycopeptides / Q000494:pharmacology*; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000139:chemically induced
D000276:Adjuvants, Immunologic; D006020:Glycopeptides; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C023868:N-acetyl-beta-glucosaminyl-N-acetylmuramyl-alanylisoglutamine